Related Experiment Video
Updated: Feb 20, 2026
14:44
Scalable Fabrication of Stretchable, Dual Channel, Microfluidic Organ Chips
Published on: October 20, 2018
27.6K
Self-contained, low-cost Body-on-a-Chip systems for drug development
Ying I Wang1, Carlota Oleaga2, Christopher J Long2,3
11 Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA.
Experimental Biology and Medicine (Maywood, N.J.)
|October 26, 2017
Summary
This review covers advancements in low-cost, self-contained Body-on-a-Chip systems for preclinical drug testing. These microphysiological systems offer reproducible, functional measurements to improve drug development efficiency.
Area of Science:
- Biomedical Engineering
- Drug Discovery
- Preclinical Research
Background:
- Integrated multi-organ microphysiological systems (Body-on-a-Chip) are crucial for preclinical drug evaluation.
- Current systems face challenges in cost, ease of operation, and reproducibility.
- Enhanced functional measurements are needed for accurate toxicity and efficacy assessment.
Purpose of the Study:
- To review progress in developing self-contained, low-cost microphysiological systems.
- To highlight systems capable of functional physiological measurements.
- To assess the potential of pumpless recirculation platforms for drug development.
Main Methods:
- Review of existing literature on microphysiological systems.
- Focus on pumpless platforms with recirculation capabilities.
- Analysis of systems incorporating functional response measurements (electrical, mechanical, barrier integrity).
Main Results:
- Development of self-contained, low-cost microphysiological systems.
- Pumpless recirculation platforms offer high reliability and ease of operation.
- Integration of functional measurements enhances physiological response monitoring.
- Systems can operate for extended periods (up to 28 days) for chronic and acute response assessment.
Conclusions:
- Multi-organ microphysiological systems show significant promise for improving the drug development process.
- Pumpless platforms represent a significant advancement in creating cost-effective and reliable multi-organ systems.
- These systems, with integrated functional measurements, are attractive for preclinical drug evaluation.
